Vidac Pharma Holding Plc (HAM:T9G)
Germany · Delayed Price · Currency is EUR 0.4900
+0.0150 (3.16%)
At close: Aug 13, 2025
Vidac Pharma Holding Company Description
Vidac Pharma Holding Plc, an investment holding company, engages in the discovery and development of medicines for oncologic and dermatologic diseases.
The company is developing VDA-1102 ointment, an anti-neoplastic agent that is in Phase 2 clinical trials for triggering apoptosis in cancer cells with minimal effects on surrounding normal cells.
It is also developing VDA-1102 IV, an anti-neoplastic agent; and VDA-1275, a potent small molecule new chemical entity that are in preclinical stage for use in the treatment of solid tumors.
The company was incorporated in 2021 and is based in London, the United Kingdom.
Vidac Pharma Holding Plc
| Country | United Kingdom |
| Founded | 2021 |
| Industry | Biological Products, Except Diagnostic Substances |
| CEO | Max Herzberg |
Contact Details
Address: 20-22, Wenlock Road London, N1 7GU United Kingdom | |
| Phone | 972 54 4257381 |
| Website | vidacpharma.com |
Stock Details
| Ticker Symbol | T9G |
| Exchange | Hamburg Stock Exchange |
| Reporting Currency | EUR |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Max Herzberg | Chief Executive Officer |
| Shuki Cohen | Chief Financial Officer |
| Sandra Gamzon | Chief Operating Officer |